The individualized novel antigen therapy Intismeran Autogene combined with Keytruda, developed jointly by MSD and Moderna, reached a major end in the phase III melanoma trial and will communicate with regulators about the marketing application. Boosted by positive news, US biotech stocks rose 1% before the market, Johnson & Johnson rose 0.5% before the market, AbbVie rose 0.3% before the market, Novo Nordisk ADR rose 0.9% before the market, Vertex rose 0.4% before the market, MSD rose 6.2% before the market, Moderna rose 66% before the market, and Novavac rose 3.91% before the market.

The individualized novel antigen therapy Intismeran Autogene combined with Keytruda, developed jointly by MSD and Moderna, reached a major end in the phase III melanoma trial and will communicate with regulators about the marketing application. Boosted by positive news, US biotech stocks rose 1% before the market, Johnson & Johnson rose 0.5% before the market, AbbVie rose 0.3% before the market, Novo Nordisk ADR rose 0.9% before the market, Vertex rose 0.4% before the market, MSD rose 6.2% before the market, Moderna rose 66% before the market, and Novavac rose 3.91% before the market.